Sepsis is a leading cause of in-hospital mortality, with more than 50% of patients developing Acute Lung Injury (ALI). Alveolar macrophages are the primary immune cells in lung tissue and play a crucial role in the pathogenesis of ALI. In this study, we investigated the potential therapeutic effects of dexmedetomidine (DEX) in both sepsis mice models of ALI and Lipopolysaccharide & Interferon gamma (LPS&IFN-γ)- stimulated macrophages, elucidating its underlying mechanism. In vivo experiments were conducted using the cecal ligation and puncture (CLP) technique to induce sepsis in mice, and intraperitoneal administration of DEX was initiated at 3, 6, 12 h post-CLP. Results showed that DEX significantly ameliorated CLP-induced lung tissue injury, impeded proinflammatory cytokine release, and reduced neutrophil infiltration. Additionally, DEX decreased M1 macrophage polarization in the lung tissue of septic mice. In vitro, experiments showed that DEX effectively attenuated the elevation of macrophage glycolysis levels induced by LPS & IFN-γ. Mechanistically, DEX treatment suppressed the phosphorylation of Pyruvate kinase M2 (PKM2) at the Y105 site and its nuclear translocation levels, thus disrupting the Warburg effect to reduce M1 cell polarization. Therefore, this work has demonstrated the role of DEX in macrophage polarization and sepsis-induced acute lung injury, providing valuable guidance for the treatment of critically ill patients with clinical sepsis.
Keywords: ALI; Dexmedetomidine; Macrophage; PKM2; Sepsis.
Copyright © 2025. Published by Elsevier Inc.